Previous 10 | Next 10 |
Dozens of healthcare stocks grew by double-digit percentages last week, and shares of these three drugmakers rose further than nearly all of their peers. Clinical trial results, coronavirus vaccine progress, and a buyout were the major factors that turned these biotech stocks into big gainers la...
In this episode of MarketFoolery , host Chris Hill chats with Motley Fool Asset Management's Bill Barker about the latest headlines from Wall Street. Two big chipmakers come together, a social media giant finds its U.S. footing, and a promising new treatment for cancer gets a boost by acquisi...
Immunomedics (NASDAQ: IMMU ) announces encouraging Phase 1 data on antibody-drug conjugate Trodelvy (sacituzumab govitecan) (formerly IMMU-132) in patients with brain tumors. The results were virtually presented at ESMO. More news on: Immunomedics, Inc., Healthcare stocks news, ...
MORRIS PLAINS, N.J., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Trodelvy delivered 150-fold and 40...
NEW YORK, NY / ACCESSWIRE / September 17, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Immunomedics, Inc. (NASDAQ:IMMU) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Gilead Scienc...
Ampio Pharmaceuticals Inc. ( AMPE ) has had a long road to FDA approval for its osteoarthritis drug called Ampion. It's been 9 years and 5 clinical trials in the making, and they are in their final push for approval. There is clear evidence suggestive of approval for Ampion in osteoarthritis o...
September 16, 2020 Palm Beach, FL – September 16, 2020 – The National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update the public on the latest information on research for a vaccin...
In a year dominated by the Covid crisis and the search for a treatment/vaccine, the last week has seen progress in the fight against cancer, and helped send the biotech sector surging. More news on: Gilead Sciences, Inc., Merck & Co., Inc., Immunomedics, Inc., , News on ETFs Read mo...
Gilead Sciences, Inc. ( GILD ) will acquire Immunomedics ( IMMU ) and the parties have entered into a definitive agreement, saying Gilead will pay $88.00 per share in cash. The transaction values Immunomedics at approximately $21 billion, approved by both the Gilead and Immunomedics Boards, an...
NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultima...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...